DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for macular dystrophy, retinal, 4 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMacular dystrophy, retinal, 4 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for macular dystrophy, retinal, 4 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
C-type lectin domain family 3 member B (CLEC3B) — CLEC3B is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet eohdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 1TN3 · 2.0 Å · ligand ETHANOL (EOH). Experimental structure, not a prediction.
What the evidence adds up to
No established therapy exists for any form of macular dystrophy. A 2013 review of retinitis pigmentosa, a related dystrophic retinal disease, states plainly that no treatment is established. A 2023 case report on Stargardt’s macular dystrophy notes there are no FDA-approved treatments or cures. A 2025 review of occult macular dystrophy describes only advances in molecular genetics and clinical characterisation, not treatment. A 2011 mini-review of pluripotent stem cells for retinal disease, including Stargardt’s macular dystrophy, discusses protocols for differentiation and transplant techniques but reports no patient outcomes.
A 2023 Australian protocol for a retrospective clinical audit aims to determine the potential misdiagnosis rate of inherited macular dystrophy as age-related macular degeneration in real-world practice. The authors state that genetic testing is not feasible for the majority of patients and that improving diagnostic accuracy is needed to target cost-efficient genetic testing when emerging treatments become available. The study has not yet reported results; it is a protocol describing a planned review of records from 1995 to 2023.
The 2013 German-language review of retinitis pigmentosa lists gene therapy, pharmacological substances, neuroprotection, electrical stimulation, retinal implants, cell transplantation, and optogenetic approaches as areas of research. It concludes that research is at different stages in each area and that, while there is no established therapy, the chances are good that at least some patients can be offered a treatment in the future. No concrete survival, response rate, or sample size data are given in any of these abstracts.
What is still missing: no completed clinical trial data for any macular dystrophy are reported in these abstracts; no drug is named as having shown efficacy in patients; the 2023 audit protocol has not yet produced diagnostic accuracy figures; patient stratification by genetic subtype is not addressed in a treatment context; and funding for large-scale trials or cost-efficient genetic testing programmes is not mentioned.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Cellular Physiology · 2011 · 90 citations
Pluripotent human stem cells for the treatment of retinal disease
AbstractDespite advancements made in our understanding of ocular biology, therapeutic options for many debilitating retinal diseases remain limited. Stem cell-based therapies are a potential avenue for treatment of retinal disease, and this mini-review will focus on current research in this area. Cellular therapies to replace retinal pigmented epithelium (RPE) and/or photoreceptors to treat age-related macular degeneration (AMD), Stargardt's macular dystrophy, and retinitis pigmentosa are currently being developed. Over the past decade, significant advancements have been made using different types of human stem cells with varying capacities to differentiate into these target retinal cell types. We review and evaluate pluripotent stem cells, both human embryonic stem cells and human induced pluripotent stem cells, as well as protocols for differentiation of ocular cells, and culture and transplant techniques that might be used to deliver cells to patients.
Annals of Medicine · 2023 · 2 citations · open access
Characterising the diagnosis of genetic maculopathies in a real-world private tertiary retinal practice in Australia: protocol for a retrospective clinical audit
AbstractPURPOSE: Accurate diagnosis of macular atrophy is paramount to enable appropriate treatment when novel treatments for geographic atrophy and macular dystrophies become available. Genetic testing is useful in distinguishing between the two conditions but is not feasible for the majority of patients in real-world clinical practice. Therefore, we aimed to investigate the potential misdiagnosis of inherited macular dystrophy as age-related macular degeneration (AMD) in real-world ophthalmic practice to assist in the development of guidelines to improve diagnostic accuracy while minimizing genetic testing for targeted patients. METHODS: Retrospective review of the medical records of patients diagnosed with AMD, which included imaging, between 1995 and 2023 from a large multidisciplinary private ophthalmic practice in Australia. We will use a stepwise method to screen for probable cases of macular dystrophy, followed by a consensus review by an expert panel. The outcomes are (1) to determine the potential misdiagnosis rate of macular dystrophy as atrophic AMD by retinal specialists and general ophthalmologists; (2) to identify clinical imaging modalities that are most useful for differentiating macular dystrophy from atrophic AMD; and (3) to establish preliminary guidance for clinicians to improve the diagnosis of macular atrophy from AMD in practice, and thereby target cost-efficient genetic testing. DISCUSSION: Improving the diagnostic accuracy of both AMD and macular dystrophy, while ensuring cost-efficient genetic testing, will improve the targeted treatment of macular diseases when emerging treatments become available.
Klinische Monatsblätter für Augenheilkunde · 2013 · 1 citations
Therapeutische Ansätze bei Patienten mit Retinitis pigmentosa
Abstract<b>Hintergrund:</b> Retinitis pigmentosa (RP) bezeichnet einen genetisch und klinisch heterogenen Formenkreis an dystrophischen Netzhauterkrankungen. Im Verlauf der Erkrankung kommt es zu zunehmenden Gesichtsfeldeinschränkungen bis hin zur Erblindung. Bisher ist keine Therapie etabliert. Durch zunehmendes Wissen über die zugrunde liegenden genetischen und pathophysiologischen Veränderungen gibt es eine Reihe von neuen Therapieansätzen, von denen einige hier vorgestellt werden sollen. <b>Methodik:</b> Es wurde eine systematische Literaturrecherche in PubMed zu definierten Stichworten durchgeführt. <b>Ergebnisse:</b> Zu den neuen Therapieansätzen gehören Gentherapie, pharmakologische Substanzen, Neuroprotektion, Elektrostimulation, retinale Implantate, Zelltransplantation und optogenetische Ansätze. <b>Schlussfolgerung:</b> In den letzten Jahren gab es einige Fortschritte in der Erforschung möglicher Therapieansätze bei dystrophischen Netzhauterkrankungen. Die Forschung ist in den einzelnen Bereichen unterschiedlich weit fortgeschritten. Obwohl es nach wie vor keine etablierte Therapie gibt, stehen die Chancen gut, dass in Zukunft zumindest einem Teil der RP-Patienten eine Therapie angeboten werden kann.
An <i>USH2A</i> variant leading to isolated maculopathy: a novel phenotype
AbstractIntroduction To describe examination and findings in a case of isolated maculopathy with genetic testing revealing an USH2A genotype.Methods/Results A 65-year-old man was found to have slowly worsening central vision in both eyes over several years. Fundus examination showed parafoveal pigmentary changes with an otherwise normal peripheral exam in both eyes. Fundus autofluorescence revealed parafoveal hypofluorescence with surrounding ring like area of hyperfluorescence, with optical coherence tomography (OCT) showing retinal thinning and parafoveal photoreceptor loss. Multifocal electroretinography (ERG) demonstrated diminished central responses, with full field ERG showing normal scotopic response and reduced photopic responses. Genetic testing for retinal dystrophies revealed a homozygous pathogenic variant in USH2A c.10342G>A, p. Glu3448Lys.Discussion USH2A-associated retinal dystrophy usually presents with a rod-cone phenotype. While reports of a cone-rod phenotype have been described, we present the first reported case of isolated maculopathy in USH2A-associated retinal dystrophy.
AbstractAbstract Stargardt’s macular dystrophy (SMD) is an autosomal recessive inherited retinal dystrophy associated with a mutation in the ABCA4 gene. Although there are no current food and drug administration (FDA)-approved treatments or cures for patients with SMD, current research avenues include nutritional supplementation, drug therapies, and gene therapy. It is a rare genetic eye disease that happens when fatty material builds upon the macula.
[Advances in the molecular genetics of occult macular dystrophy].
AbstractOccult macular dystrophy is an inherited macular disorder associated with cone degeneration. The characteristic clinical feature is decreased visual acuity despite a normal fundus appearance on ophthalmoscopy. Optical coherence tomography, infrared reflectance imaging, visual field testing, and multifocal electroretinography may detect structural and functional abnormalities in the macular region. This article reviews the latest advances in both domestic and international research, summarizing the clinical characteristics, pathogenic genes, genetic features, and molecular mechanisms, aiming to enhance clinical understanding of the disease and provide insights for further research and therapeutic exploration.
International Journal of Surgery Science · 2019 · 0 citations · open access
Childhood idiopathic bilateral macular dystrophy (New entity)
AbstractMacular dystrophies correspond to hereditary diseases affecting the macular region and associating primary abnormalities of the pigment epithelium and the sensory retina, which appear in children or young adults, the aim of this work is to report an atypical case of idiopathic bilateral macular dystrophy observed in a 9-year-old child. It is a new clinical entity of macular dystrophies in children, which remains rare and can be complicated by choroidal neovascularization.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
